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ABSTRACT
Lung cancer remains the leading cause of cancer- related 
deaths worldwide in women and men. In incidence, 
lung cancer ranks second, surpassed by breast cancer 
in women and prostate cancer in men. However, the 
historical differences in mortality and incidence rate 
between both sexes have changed in the last years. In 
the last decades, we have also witnessed an increased 
number of lung cancer in female never- smokers. These 
disparities have grown our interest in studying the impact 
of the gender and sex in the presentation of lung cancer. 
The aetiology is yet to be fully elucidated, but the data are 
clear so far: there is a growing divide between lung cancer 
presentation in women and men that will change our 
management and study of lung cancer. This article aims to 
review the sex and gender differences in lung cancer.
INTRODUCTION
Lung cancer remains the leading cause of 
cancer- related deaths for men and women 
globally.1 Despite of the encouraging overall 
cancer mortality predictions for 2020 in the 
European Union pointed out by Carioli et 
al, the highest cancer mortality rates were 
predicted for lung cancer for both sexes. The 
authors revealed a narrowing of male–female 
gap in lung cancer rates in the last 5 years with 
a decrease among men (9.2%) whereas an 
increase of rates among women is reported 
(6.0%).2 Nevertheless, recent reports of US 
National Institutes of Health (NIH) high-
lighted a decrease of lung cancer death rates 
(−4.8%) per year among men and (−3.7%) 
per year among women.3
Both the incidence and mortality of lung 
cancer are strongly connected to cigarette 
smoking. Thus, both had risen for several 
years before starting to decline for men and 
plateauing for women in the first tobacco 
epidemic countries, mirroring the different 
smoking history between both sexes.4 It is 
worth remembering as the societal roles of 
women began to closely epitomise those 
of men, the risk for women rose signifi-
cantly, reaching similar levels.5 Likewise, this 
tendency follows the initiation of compre-
hensive smoking control programmes and 
campaigns.4 These trends occurred earlier 
in industrialised countries than in the devel-
oping ones, where the tobacco epidemic 
occurred later following the adoption of 
western lifestyle. In the USA and most of 
Western Europe, male lung cancer incidence 
and mortality rates have indeed been drop-
ping since the 1990s.1 Furthermore, econom-
ically emerging nations (eg, Brazil, Russia, 
India, China and South Africa states) and 
low/middle- income countries showed varied 
incidence rates depending on religious back-
ground, environmental and occupational 
factors, consumption of smokeless tobacco 
including dip, snuff, snus and chewing 
tobacco, and life expectancy, among others. 
Unfortunately, high lung cancer incidence 
countries exhibit higher related mortality 
burden compared with wealthier countries.1
However, an in- depth analysis of the lung 
cancer incidence related to tobacco consump-
tion in many western countries revealed the 
existence of deep inequalities regarding to 
tobacco use, with vulnerable populations such 
as certain racial/ethnic groups, low educa-
tional and/or socioeconomic level groups, 
people with mental diseases, lesbian, gay, 
bisexual and transgender community, among 
others being more exposed to smoking.6 7
In addition, Jemal et al, focused on lung 
cancer incidence among young adults, 
finding sex- based incidence divergences with 
higher incidence among young women not 
attributed to smoking habits; particularly 
among the adenocarcinoma (ADC) subtype.8
Furthermore, numerous studies have been 
conducted in order to analyse smoking habits 
among teenagers, evoking risk factors such as 
the search of social recognition and approval 
among their smoker peers; close relatives and 
family smoking; parental educational status, 
parental control and relationship, socioeco-
nomic level, secondhand exposition leading 
to nicotine dependence, ads by their idols, 
curiosity, attention troubles, stress, psycho-
logical burden and parenteral rivalry, as well 
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as low perceived risk, among others.9–11 In 2017, Arrazola 
et al revealed in their Global Youth Tobacco Survey across 
61 countries that smoking prevalence among students 
between 13 and 15 years was about 11%, with a median of 
14.6% among males and 7.5% among females.12
Different national initiatives aimed at decreasing adoles-
cent smoking have already been implemented. These 
include increasing the minimum age of sale for tobacco 
products as well as the selling prices of tobacco prod-
ucts; carrying out public campaign to decrease tobacco 
promotions, buoying up the establishment of tobacco- 
free places, involving their idols in these programmes 
and forbidding smoking in indoor and mutual places.13 
Furthermore, performing instructive programmes about 
negative consequences of tobacco use; implicating 
parents and families in these programmes; and supplying 
available therapeutic options and counselling for tobacco 
dependence.
Another subject of further consideration, it is lung 
cancer among never- smokers. Never- smoker is an indi-
vidual who has never smoked or who has smoked 
fewer than 100 cigarettes in their lifetime and does not 
currently. Several studies have shown an increased rate 
of never- smoker female lung cancer cases (over 50% of 
lung cancer women). In contrast, men had an incidence 
of about 15%. In Asia, this incidence is higher, reaching 
about 80% of cases.14–18 Despite of this increased inci-
dence, never- smoker lung cancer has lower mortality rates 
than former- smoker and current- smoker lung cancer.18 19 
In fact, never- smoker lung cancer is deemed a different 
pathology taking into account its distinct epidemiolog-
ical, clinical, histological, molecular and prognostic 
features.20 The aetiology of never- smoker lung cancer is 
yet to be clarified. Nevertheless, several risk factors have 
been evoked such as genetic, occupational, hormonal, 
microbiological and environmental factors.21–24
Here, we will discuss the epidemiology of lung cancer 
and the impact of sex and gender in these setting, and 
possible hypotheses explaining oncological disparities 
between males and females.
Sources and selection criteria
We identified references for this review by performing 
a PubMed, Cochrane Library electronic databases, and 
Google Scholar search for years 1970 to 2020. Search terms 
used in strategic combination to identify germane articles 
included “cancer”, “lung cancer”, “women”, “incidence”, 
“mortality”, “Europa”, “sex”, “gender”, “sex hormones”, 
“oncogenic drivers”, “immunotherapy”, “chemotherapy”, 
“survival”, “screening”, “teenagers”, “smoking”, “nico-
tine”, “genetic alterations”, “virus”, “histology”, “occupa-
tion” and “psychosocial”. We included in vitro, animal 
and human studies, including meta- analyses. Only arti-
cles published in English were reviewed. In all cases, we 
used the highest level of evidence available to inform this 
review, with more recent studies cited where possible.
We also acceded WHO, American Society of Clin-
ical Oncology (ASCO), European Society for Medical 
Oncology and Centers for Disease Control and Prevention 
(CDC) websites for current cancer statistics and guide-
lines. The recent presentation performed by Gonzaga at 
2019 annual Canadian Cardiovascular Congress was also 
reviewed.
The final reference list was based on relevance to the 
topics covered in the review and was modified on the 
basis of comments from peer reviewers.
Gender and sex differences
Over the course of the last 25 years, there has been a 
growing interest in the possible differences in the pres-
entation of lung cancer in women compared with men: 
age at diagnosis, incidence, biology and natural history, 
response to anticancer therapy, immune responses and 
mortality. This interest is obvious, considering well- known 
divergences in sex as determined by our physiological 
and anatomical features, as well as, in gender conditioned 
by our behaviour and actions regulated by society, reli-
gious or cultural backgrounds. Furthermore, these differ-
ences became more ostensible when the characteristics of 
oncogene addicted non- small- cell lung cancer (NSCLC) 
patients were highlighted.
Despite a vast research, the landscape is intricate, not 
entirely understood and inconclusive. Multiple statements 
have emerged from countless studies which are not always 
consistently observed; most remain speculative. These 
statements include higher susceptibility to lung cancer 
in women compared with men, inferior cessation rates 
among female smokers compared with their male coun-
terparts, the predominance of ADC in women, different 
tumour responses and immune responses between men 
and women, and the higher frequency on never- smoking 
among female lung cancer.1 25
As discussed later, all these issues have been attributed 
to several causes such as the metabolism of carcinogens, 
genetic differences, social roles, environmental expo-
sures, hormonal factors and oncogenic viruses.
SEX-RELATED ITEMS
Sex differences involve biological, physiological, 
hormonal and genetic factors. This topic has been broadly 
studied and has generated controversial results. Differ-
ences between sexes are inconsistent across studies. Here, 
we expose some theories evoking metabolic, genetic, 
hormonal, viral, immune and histological causes.
Tobacco-related carcinogens metabolism
There is a theory that females are biologically more 
susceptible to the effects of carcinogens than males. This 
is supported by epidemiological data showing that female 
smokers have a higher likelihood of developing lung 
cancer compared with male smokers. Females with an 
estimated 40 pack- year smoking history had a threefold 
higher ORs (27.9% vs 9.3%) of developing lung cancer 
compared with males with the same smoking habits.26
Tobacco smoke is a mixture of more than 7000 chem-
ical compounds, among them, 70 are known to cause 
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cancer, based on evidence for carcinogenicity from 
either laboratory, animals or humans research. There are 
various classes of chemicals such as polycyclic aromatic 
hydrocarbons, aza- arenes, N- nitrosamines, volatile hydro-
carbons, ethyl carbamate, ethylene oxide, nickel, chro-
mium, cadmium, polonium-210, arsenic and hydrazine.27
The polycyclic aromatic hydrocarbons are activated 
by the phase I carcinogen- activating enzymes (ie, cyto-
chrome P450, mono- oxygenases) which are coded by cyto-
chrome P450, family 1, subfamily A, member 1 (CYP1A1) 
genes. Phase II enzymes contend with phase I enzymes, 
inhibiting the formation of free radicals and catalysing 
the conversion of reactive intermediates to inactive conju-
gates. If these metabolites are not inactivated, they bind 
to DNA, constructing DNA adducts.28
It must be emphasised that nicotine is not a carcinogen, 
but it is the addictive constituent of smoke, inhibiting 
the smoking cessation due to compulsive drug- seeking 
behaviour, even in the face of negative health conse-
quences.29 According to CDC in 2010, only 6.2% of 
smokers give up definitively smoking.30
Subsequently, numerous studies have indicated that 
women metabolise smoke carcinogens differently from 
men. These studies are inconclusive, those on animals 
showed a lower nicotine metabolism.31 32 By contrast, Klein 
and Gorrod conducted a study on a group of smokers in 
the UK that found no gender difference in nicotine expo-
sure.33 These results were confirmed by Rubinstein et al 
who did not find significant differences either by gender 
or self- reported hormone use.34
Two potential mechanisms may explain these findings. 
First, the imbalance between metabolic activation and 
detoxification of carcinogens.35 36 Second, a defective 
DNA repair system.37
In fact, gene expression studies provide a possible 
rationale for the increased risk of lung cancer among 
female smokers. Female smokers have a higher expres-
sion of CYP1A1 genes in the lungs than males, resulting 
in greater carcinogen activation.38 This increased expres-
sion might be hormone induced, as mentioned below.39
Furthermore, women exhibit a more prominent poly-
morphism in the phase II detoxification enzymes, mainly 
glutathione S- transferase M1 null genotype gene deletion 
induced.40 This could again favour the accumulation of 
free radicals and carcinogenic metabolites.
Additionally, other studies have shown that women 
have higher levels of DNA adducts than men. High levels 
of stable adducts in lung tissue are believed to play a role 
in the initiation of carcinogenesis.41
Finally, it is well known that a reduced capacity for DNA 
repair is associated with an increased risk of lung cancer. 
Preclinical data suggest that women have lower DNA 
repair capacity than men.42
Genetic factors
Several studies have reported a higher frequency of more 
critical driver genes among women, such as tumour 
protein 53 (TP53) suppressor gene and the V- Ki- ras2 
Kirsten rat sarcoma viral oncogene homolog (KRAS); this 
is explained by a higher predisposition to molecular aber-
rations among women as a consequence of the carcino-
genic effects of tobacco smoke.43
Some studies have found an earlier activation and 
higher expression of peptide stimulating cell prolifer-
ation, the gastrin- releasing peptide receptor (GRPR) 
explaining the greater risk of lung cancer among women. 
Shriver et al detected GRPR messenger RNA (mRNA) 
expression more frequently in female non- smokers than 
in male non- smokers (55% and 0%, respectively).44
In addition, a major lung cancer susceptibility locus was 
also found to map to chromosome 6q23-25. Even light 
smoke exposure greatly increased the risk in individuals 
with inherited susceptibility.45
Furthermore, among northeast Chinese female 
non- smokers, two single nucleotide polymorphisms, 
rs4787050 and rs8045980 were associated with a signifi-
cantly increased risk of lung cancer, a risk further exacer-
bated by exposure to cooking oil fumes.46
A subset of lung ADC is related to the activation of 
potent proto- oncogenes, called drivers. Somatic driver 
genetic alterations, including epidermal growth factor 
receptor (EGFR) mutations, occur more frequently in 
non- smokers, and particularly, women with ADC. Exon 
18 mutations have been linked to genetic polymorphisms 
associated with oestrogen biosynthesis and metabolism in 
never- smoking females with ADC. Mutations in human 
epidermal growth factor receptor 2 (HER-2) exon 20 
occur in 1%–5% of patients, particularly young never- 
smoker women. By contrast, there are no sex differ-
ences among other oncogene- addicted tumours such 
as anaplastic lymphoma kinase (ALK) or ROS proto- 
oncogene 1 receptor tyrosine kinase (ROS-1) addicted 
lung carcinomas.47
Hormonal factors
There remains a controversy about the potential influ-
ence of reproductive and hormonal factors involving 
parity, age at menarche and menopause on lung cancer.
Data regarding the impact of hormonal replacement 
therapy (HRT) on the risk for lung cancer in women is 
inconsistent. An increased risk associated with HRT disap-
pears after adjusting for smoking and other confounding 
factors. In a study by Chlebowski et al, HRT in postmeno-
pausal women did not increase incidence of lung cancer, 
yet it increased the mortality of women already affected 
by NSCLC.48 49
The controversy remains, another analysis of more than 
36 000 perimenopausal and postmenopausal women 
showing, after adjusting certain possible confounding 
factors, an association between HRT use and lung cancer 
incidence in a duration- dependent manner, with an 
approximate 50% increased risk for use of 10 years or 
longer.50
A prospective, observational study, the French Collab-
orative Intergroup for Thoracic Cancer Research, (IFCT-
1002) BioCAST study, in 260 female never- smokers with 
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lung cancer showed that reproductive factors were associ-
ated significantly with specific lung cancer mutations. In 
particular, EGFR mutations were correlated significantly 
with increasing age at menarche and age at first birth. In 
addition, ALK alterations were associated with both parity 
and number of pregnancies.51
In terms of the association between risk of lung cancer 
and reproductive factors, the American NIH- American 
Association of Retired Persons cohort including 185 017 
women, suggested late menarche was a protective factor, 
while early menopause was identified as a risk factor for 
lung cancer.52 While correlation has been demonstrated, 
there is yet to be clear causality.
The relevance of oestrogen receptors (ER) expression 
in lung ADC appears minimal. Lee et al investigated the 
expression of the female sex hormone receptors, ER 
alpha, ER beta, and progesterone receptor in lung ADCs. 
The expression of each receptor exhibited associations 
with certain clinic- pathological features and prognostic 
factors; however, in multivariate analysis, none of the 
female sex hormone receptors were significantly associ-
ated with patient survival.53
In vitro studies are inconsistent regarding the potential 
role of oestrogen. It may be involved in lung carcinogen-
esis through promotion of cellular proliferation, both 
acting on fibroblasts and activating intermediates that 
produce DNA adducts.54 Moreover, in vitro studies have 
reported that ER and EGFR pathways have operating 
synergy.55 These observations have led to in vivo studies 
and clinical trials evaluating the association of an ER 
antagonist (fulvestrant) and EGFR- tyrosine kinase inhibi-
tors (EGFR- TKI). Stabile et al found that the combination 
decreased cell proliferation and incremented apop-
tosis.56 Nevertheless, the phase II IFCT-1003 LADIE Trial 
reported this association does not improve the outcome 
compared with EGFR- TKI regardless of EGFR status.57
Viral factors
Human papillomavirus (HPV) infection has been 
suggested to participate in lung carcinogenesis. Asian 
studies have reported a prevalence of pulmonary HPV 
infection in lung ADC of 9%–42%. In contrast, western 
studies show a lower prevalence. The small cohorts and 
diverse diagnostic methods with variable ranges of sensi-
tivity/specificity, as well as the heterogeneous expression 
of HPV prevent any firm conclusions to be made.58
Immune factors
Germane dissimilarities in immune response between 
men and women have been disclosed in many studies, 
mirroring tangled interplay among the factors mentioned 
above. The stronger immune responses reported in 
women have been attributed to sex chromosome linked 
genes and miRNA, coding for proteins involved in the 
regulation of the innate and acquired immunity; differ-
ences in microbial composition, in programmed death- 
ligand 1 (PD- L1) expression, hypothetically modulated 
in an oestrogen- dependent manner (evidence- based in 
preclinical studies); and proportion of intratumoural 
immune infiltrates.59 60
Histological factors
ADC has become the most common histological variant 
in both sexes, but more women than men are diagnosed 
with ADC. This switch in the incidence of histological 
subtypes is mainly related to the change in cigarette 
manufacturing with the introduction of filtered cigarettes 
(smaller particles were able to travel deeper in the lungs, 
where they cause ADC, rather than more proximal squa-
mous cell carcinoma), the reduction of smoking preva-
lence among men, and the later onset of smoking filtered 
cigarettes among women.61
Another theory is based on the unequal reduction in 
different histological subtypes following smoking cessa-
tion. For example, data have shown that after quitting 
smoking, the risk of developing small cell carcinoma 
decreases by about 17% per year, while the decrease in 
ADC is only 8% per year potentially revealing why there 
may be increased incidence rates of ADC among female 
populations.62
GENDER-RELATED ITEMS
Our gender features are conditioned by our behaviour 
and actions regulated by society, religious or cultural 
background. These behaviours can determine our occu-
pation, lifestyle, smoking’s age onset, smoking ways, type 
of cigarettes, among others.
Occupational and residential factors
It has been accepted for a long time that certain employ-
ments predispose to greater risk of lung cancer. In fact, 
occupational exposures are the second most significant 
risk for lung cancer. Unfortunately, most studies evaluating 
occupational lung carcinogens have been performed in 
traditionally predominantly male occupations. Conse-
quently, we know that occupations in metallurgy, mining 
and building are sources of lung carcinogens. With the 
advent of female emancipation, during the second world 
war, many women engaged in several professional activ-
ities and, a few studies emerged in order to analyse this 
topic in the female population. Risky female occupations 
are different from risky male occupations. In fact, some 
studies have found a higher risk of lung cancer in hair-
dressers, nails salon workers, housemaids, laundry/dry 
cleaners and, catering and cooking.63
Aside from specific occupations, women spend more 
time in the home, therefore, they are more exposed to 
indoor pollution, for example, to high levels of radon; 
another important risk factor of lung cancer.64
Psychosocial factors
Psychosocial hypotheses have been put forward to explain 
the gender differences on smoking and tobacco cessa-
tion. This remains a sensitive topic, subject to pre- existing 
stereotypes, and data should be taken with caution.
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Several studies observe a poorer rate of smoking cessa-
tion among women, although some did not find differ-
ences. Anxiety, depression, high levels of stress, both 
professional and at home (childcare) are thought to be 
likely causal factors.65
Recently, Gonzaga presented the results of a study of 
more than 200 smokers at the 2019 Canadian Cardiovas-
cular Congress: showing that women are half as likely to 
quit smoking as men. In her study, women had a higher 
prevalence of anxiety or depression than men (41% vs 
21%, respectively), which potentially affected the smoking 
cessation process.66
On other hand, a study published by Martin showed 
that smokers who were partnered at baseline were more 
likely to quit than those who were not partnered and; 
those who had a non- smoking partner throughout were 
more likely to give up. Those who had a partner who 
smoked at baseline but stopped smoking in the following 
4 years were even more likely to drop out.67
It has been hypothesised that men and women smoke 
for different reasons. Women smoke to improve frame 
of mind, self- esteem, to lose weight or responding to 
tobacco- related cues. Men smoke in order to increase 
reward effects of nicotine.68
Another risk factor importantly influenced by gender 
is secondhand smoke, which increases the risk of lung 
cancer by about 20%. It has been reported that women 
are more affected by this problem, including in their 
own homes where they often lack the power to negotiate 
smoke- free spaces. In addition, women, as well as chil-
dren, are more exposed to thirdhand smoke (residual 
nicotine and other chemicals left on indoor surfaces by 
tobacco smoke).69
Historically, tobacco companies have developed adver-
tising tactics tailored particularly towards women in order 
to make cigarette smoke more palatable or addictive. 
Examples include the introduction of menthol as a ciga-
rette additive, filtered and low- tar versions, cigarettes with 
fashionable names and sophisticated colours, and even 
alleging its powerful role on the control of weight gain or 
its relaxing and antidepressant powers.
IMPLICATIONS OF SEX DIFFERENCES
Sex and gender differences have implications on 
screening, response to therapy and prognosis.
On screening
Large randomised trials on low- dose CT screening such 
as the Dutch- Belgian lung- cancer screening (Nederlands- 
Leuvens Longkanker Screenings Onderzoek, NELSON) 
trial and National Lung Screening Trial (NLST) have 
demonstrated a meaningful decline in lung cancer 
mortality of 26% and 20%, respectively. Women have 
been under- represented in these trials. However, despite 
of not being included in the primary endpoint popu-
lation and consequently leading to an underpowered 
subgroup analysis, the reduction of mortality was 61% in 
females in NELSON trial and 26% in NLST. Although, 
post hoc analyses from the NLST showed slight differ-
ence after adjusting by histological subtype; an extended 
follow- up (12 years) study of the NLST cohort revealed 
a lung cancer mortality risk ratio (RR) lower for women 
(RR=0.86) than for men (RR=0.97).70
In the German Lung Cancer Screening Interven-
tion trial, Becker et al showed a significant reduction 
in lung cancer mortality among women (HR=0.31) but 
not among men (HR=0.94). According the authors, 
this curious difference could be explained either by the 
tumour histological heterogeneity between both sexes, or 
it could be due to chance.71
On the other hand, a retrospective cohort study anal-
ysed the application of current screening guidelines 
among more than 200 women diagnosed of lung cancer. 
Around 80% of female lung cancer patients did not meet 
the lung cancer screening criteria: this leads us to rethink 
our screening criteria considering that 20% of lung 
cancers are not attributed to tobacco.72
Multiples efforts are being carried out in order to 
deploy an international uniform screening programme. 
These items related to sex differences should be taken 
into account. Probably, women have to be screened at 
lower pack- years than men and at a younger age; taking 
into account the findings of the updating of International 
Early Lung Cancer Action Programme (I- ELCAP), which 
indicate that women are at higher risk of lung cancer 
than men at a similar age and smoking history.73
Up until now, the screening criteria involve adults aged 
55–80 years who have a 30 or more pack- year smoking 
history and currently smoke or have quit within the past 
15 years.
On response to therapy and prognosis
A myriad of studies have demonstrated that women have a 
better response to therapy regardless of therapeutic modality, 
stage, histological subtype, smoking status, even after 
adjusting for gender- specific life expectancy.74
Evidence has long suggested that there are sex differences in 
chemotherapy toxicity and cytotoxic response. For instance, 
Wakelee et al evaluated whether sex affected survival in the 
Eastern Cooperative Oncology Group E1594 trial. Patients 
with stage IIIB or IV were randomised to receive different 
platinum based chemotherapy treatment arms. Women had 
a 1.9- month statically significant improvement in median 
survival compared with men, despite similar response rates 
and greater toxicity.75
The influence of sex dimorphism in microbiome compo-
sition is suggested as another cause of the dissimilarity on 
response and toxicity to anticancer therapies, between women 
and men.60 However, it is extremely difficult to draw conclu-
sions about the influence of microbiome in therapeutic 
response, taking into account myriad items influencing in 
the microbiota’s composition and tumour response to anti-
cancer therapies.
Additionally, these observations could be attributed to 
differences in drug metabolism, toxicity and diminished 
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DNA repair capacity (which could explain their higher sensi-
tivity to platinum drugs).
The sex differences on immune responses could influence 
on response to immunotherapy, though no firm conclusion 
can be drawn at this time regarding immune checkpoint 
inhibition in cancer.
A meta- analysis by Conforti et al including 20 randomised 
trials in which anti- cytotoxic T- lymphocyte- associated protein 
4 (CTLA-4) and anti- programmed cell death 1 (PD-1) 
antibodies were administered alone or with other agents 
such as chemotherapy or other immunological agents and 
compared with placebo or non- immunological agents, 
reported a greater overall survival in male compared with 
female patients.76
These results should be interpreted with caution given the 
high heterogeneity in tumour types. A recent update of this 
meta- analysis but including only randomised controlled trials 
testing anti- PD-1 or PD- L1 given either alone or combined 
with chemotherapy, as first- line systemic treatment for patients 
with advanced NSCLC showed that women with advanced 
lung cancer derived a statistically significantly larger benefit 
from the addition of chemotherapy to anti- PD-1/PD- L1 than 
men. The authors ascribed these findings to the ability of 
chemotherapy to increase the mutational burden and neoan-
tigenic load of lung cancer in women.77
In a similar analysis, Wallis et al disclosed no statistically 
significant association between sex and overall survival 
in more than 13 000 patients with solid tumours from 23 
randomised clinical trials treated by anti- PD- L1 checkpoint 
inhibitors.78
Regarding prognosis, a Swedish population- based cohort 
study concluded that women have a better prognosis after 
adjustments for several factors in early stage NSCLC and lung 
ADC.79 Additionally, Albain et al showed, in a prospective 
case series intergroup study of Southwest Oncology Group 
(SWOG S0424), that women, regardless of smoking history, 
type of therapy, hormonal factors or mutational status, had 
significantly better overall survival rates compared with 
men.80
Recently, the updated I- ELCAP found that women’s 
survival rates were 87.3% higher than the men’s survival 
rates, after adjusting for age, smoking history, disease stage, 
histology and resection.73
Similarly, given the increased incidence of EGFR and 
HER-2 oncogene addicted lung cancers in women and the 
effective therapeutic arsenal for these diseases, an improved 
prognosis is expected.
Recently, a Spanish study presented at the 2019 ASCO 
Annual Meeting showed that the median overall survival was 
12 months for men and 19 months for women diagnosed 
with NSCLC. Women with stage IV NSCLC harbouring an 
EGFR sensitising mutation were found to outlive men as well, 
with men and women having median survival of 19 and 32 
months, respectively.81
CONCLUSIONS
In recent years, there has been much focus on the impact of 
sex and gender differences in lung cancer. While genetic and 
biological difference between men and women could explain 
the disparity in incidence and mortality of lung cancers, much 
remains unanswered. The degree which gender- associated 
habits, genetics and environmental exposure to carcinogenic 
agents participate in these differences is unclear.
The data so far are clear: there is a growing divide between 
lung cancer incidence in women and men. Future studies 
should investigate the potential demographic, environmental 
and behavioural factors that may be driving these findings, 
with the aim of tailoring interventions or programmes to 
reduce the incidence of lung cancer among females.
A review of the screening criteria will in particular be 
necessary to take account of female smoking history and 
lung cancer diagnosis. Further research including prospec-
tive clinical trials is warranted to customise our therapeutic 
decision making based on sex and gender.
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